FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lehoux Lawrence		 2. Date of Event Requiring Statement (MM/DD/YYYY)
7/9/2021 

 3. Issuer Name and Ticker or Trading Symbol

CEN BIOTECH INC [CENBF]
(Last)        (First)        (Middle)

300-3295 QUALITY WAY		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Technology Officer /
(Street)

WINDSOR, ONTARIO, CANADA, A6 N8T 3R9      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3030000 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Lawrence Lehoux (the "Reporting Person") was appointed to his positions with CEN Biotech, Inc. (the "Issuer") on July 9, 2021 and owned 3,030,000 shares of the Issuer's common stock at such date.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lehoux Lawrence
300-3295 QUALITY WAY
WINDSOR, ONTARIO, CANADA, A6 N8T 3R9		X
Chief Technology Officer
Signatures
/s/ Lawrence Lehoux7/21/2021
**Signature of Reporting PersonDate
CEN Biotech (CE) (USOTC:CENBF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos CEN Biotech (CE).
CEN Biotech (CE) (USOTC:CENBF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos CEN Biotech (CE).